TherapeuticsMD, Inc. — Director's Dealing 2020

Aug 8, 2020

SEC Form 4/A — Form 4/A

Issuer: TherapeuticsMD, Inc. (TXMD)
CIK: 0000025743
Period of Report: 2020-06-18

Reporting Person: DArecca James (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-06-18	Performance Stock Units	$0	A	151500	Acquired		Common Stock (151500)	Direct
2020-06-18	Restricted Stock Units	$0	A	651500	Acquired		Common Stock (651500)	Direct

Footnotes

F1: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer.

F2: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning June 1, 2021 (the one-year anniversary of the date of the reporting person's appointment as Chief Financial Officer), becoming fully vested on June 1, 2023.